Research Topics
Genomes and Genes | Shinsuke IidaSummaryAffiliation: Nagoya City University Country: Japan Publications
| Collaborators
|
Detail Information
Publications
Multistep tumorigenesis of multiple myeloma: its molecular delineationShinsuke Iida
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Science, Nagoya, Japan
Int J Hematol 77:207-12. 2003..An accurate understanding of each of these molecular events should help clarify the development of specific molecular targeting therapies based on the differences in dysfunctional signaling pathways found in the cells of all MM patients...
Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myelomaShinsuke Iida
Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho cho, Mizuho ku, Nagoya, Japan
Int J Hematol 92:118-26. 2010..In conclusion, 25 mg of lenalidomide was given safely as a single agent or in combination with dexamethasone in Japanese patients. The good efficacy of the combination therapy was also demonstrated in this study...- A novel human multiple myeloma-derived cell line, NCU-MM-1, carrying t(2;11)(q11;q23) and t(8;22)(q24;q11) chromosomal translocations with overexpression of c-Myc proteinS Iida
Second Department of Internal Medicine, Nagoya City University Medical School, Japan
Int J Hematol 72:85-91. 2000.... - Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32)S Iida
Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
Leuk Lymphoma 34:25-33. 1999.... - A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma modelFumihiko Sato
Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, Aichi, 467 8601, Japan
Cancer Immunol Immunother 59:1791-800. 2010..In the near future, the efficacy of this type of CDC-enhancing antibody will be determined in clinical trials in humans... - Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivoAsahi Ito
Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467 8601, Japan
J Immunol 183:4782-91. 2009..Furthermore, the potent ADCC mediated by defucosylated anti-CCR4 mAb, observed here in vivo in humanized mice, will be exploited in clinical trials in the near future... - Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCCAtsushi Inagaki
Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
Int J Cancer 125:212-21. 2009..The ULBPs could be valuable diagnostic biological markers and significant targets for immunotherapy to improve efficacy not only of rituximab but also of other therapeutic mAbs... - Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1Masaki Ri
Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, Aichi, Japan
Cancer Sci 100:341-8. 2009..Taken together, we conclude that bortezomib-induced apoptosis in ATLL and CTCL cells at least partly depends on the upregulation of Noxa and functional repression of Mcl-1, as is also the case in MM and malignant melanoma... - Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndromeHiroki Yano
Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
Clin Cancer Res 13:6494-500. 2007.... - The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarityJianmin Ding
Department of Medical Oncology and Immunology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
Blood 114:3325-8. 2009..This finding provides a new insight into the mechanism of disease causation by mutations in the TMD of cytokine/hematopoietic receptors... - CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecifiedTakashi Ishida
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Clin Cancer Res 10:5494-500. 2004..We suggest that a specific therapy targeting the CCR4 molecule may be developed as an alternative treatment for patients with CCR4-positive tumors... - Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphomaToshihiko Ishii
Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
Clin Cancer Res 16:1520-31. 2010..The second aim was to fully elucidate the mechanism of antibody-dependent cellular cytotoxicity (ADCC) mediated by this defucosylated monoclonal antibody... - Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilegeTakashi Ishida
Department of Internal Medicine and Molecular Science and Clinical Pathology, Nagoya City University Graduate School of Medical Sciences, Kawasumi, Mizuho chou, Mizuho ku, Nagoya shi, Aichi, Japan
Cancer Res 66:5716-22. 2006.... - Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myelomaHiroki Yano
Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
Cancer Sci 99:2309-14. 2008..When a combination of CPT-11 and bortezomib was administered, the subcutaneous tumors completely disappeared. Thus, clinical trials on CPT-11 in patients with relapsed or refractory MM are warranted... - The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphomaTakashi Ishida
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan
Clin Cancer Res 10:7529-39. 2004.... - Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reportsTatsuya Yoshida
Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, 467 8601, Japan
Int J Hematol 91:844-9. 2010..Establishment of a standard strategy to prevent HBV reactivation is important for myeloma patients receiving systemic chemotherapy... - Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphomaSusumu Suzuki
Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Japan
Cancer Sci 103:1764-73. 2012..The present study not only provides a strong rationale for exploiting Tax as a possible target for ATL immunotherapy but also contributes to our understanding of the immunopathogenesis of ATL... - Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factorsAtsushi Inagaki
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Mizuho-ku, Nagoya-shi, Aichi, Japan
Int J Cancer 118:3054-61. 2006..Measurement of serum IL-5 and IL-10 levels is useful for predicting the prognosis and for determining a suitable treatment strategy for ATLL patients... - Regulatory T-cell function of adult T-cell leukemia/lymphoma cellsHiroki Yano
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Mizuho chou, Mizuho ku, Nagoya shi, Aichi, Japan
Int J Cancer 120:2052-7. 2007..e., how HTLV-1-infected cells can survive in the face of host immune responses. It also adds to our understanding of ATLL patients' severely immunocompromised state... - Angioimmunoblastic T-cell lymphoma mice modelFumihiko Sato
Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, Aichi 467 8601, Japan Department of Anatomic Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, Aichi 467 8601, Japan
Leuk Res 37:21-7. 2013..This is the first report of reconstituting follicular helper T (TFH) function in AITL cells in an experimental model, and this is consistent with the theory that TFH cell is the cell of origin of AITL tumor cells... - Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse modelAsahi Ito
Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, Aichi, Japan
Cancer Immunol Immunother 58:1195-206. 2009..The second aim was to evaluate ADCC mediated in these humanized mice by the defucosylated anti-CC chemokine receptor 4 (CCR4) monoclonal antibody (mAb) which we have developed and which is now in phase I clinical trials... - CC chemokine receptor 4-positive diffuse large B-cell lymphoma involving the skin: a case reportTakashi Ishida
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Japan
Int J Hematol 82:148-51. 2005..To the best of our knowledge, this report is the first of a CCR4-positive B-cell lymphoma. The present case provides new insights into the pathogenesis of skin involvement in B-cell lymphomas... - Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcomeTakashi Ishida
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Science, Nagoya 467-8601, Japan
Clin Cancer Res 9:3625-34. 2003..Multivariate analysis confirmed that CCR4 expression was an independent and significant prognostic factor (P < 0.05). Thus, our finding may provide a novel insight into not only the biological but also the clinical features of ATLL... - Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasiaKazuhisa Miura
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Science, Mizuho ku, Nagoya 467 8601, Japan
Cancer Sci 94:350-4. 2003..This suggests to us that cyclin D1 deregulation due to the presence of t(11;14) is involved in the early development of plasma cell neoplasms, and that this event alone is not enough for the development of symptomatic myeloma... - ABO genotype and the risk of gastric cancer, atrophic gastritis, and Helicobacter pylori infectionMakoto Nakao
Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Chikusa ku, Nagoya, Japan
Cancer Epidemiol Biomarkers Prev 20:1665-72. 2011.... - T-cell acute lymphoblastic leukemia as a secondary leukemia after a 3-year remission of acute myelocytic leukemiaKazuya Tsuboi
Second Department of Internal Medicine, Nagoya City University Medical School, Japan
Int J Hematol 77:518-21. 2003..We thought that this case would be extremely valuable for studying the etiology and biological characteristics of T-cell ALL as a secondary leukemia after AML... - Induction of class II major histocompatibility complex expression in human multiple myeloma cells by retinoidTakaomi Sanda
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho cho, Mizuho ku, Nagoya, Aichi, Japan
Haematologica 92:115-20. 2007..This is the first report demonstrating that retinoid can induce the expression of MHC II in terminally-differentiated plasma/MM cells... - Lymphoid blastic crisis of chronic myelogenous leukaemia with inv(16)(p13;q22)Kazuya Tsuboi
Second Department of Internal Medicine, Nagoya City University Medical School, Mizuho ku, Nagoya 467 8601, Japan
Leuk Res 26:771-4. 2002..To date, lymphoid BC of CML having inv(16)(p13;q22) abnormality has not been reported. The case presented here could be a clue to understand the pathophysiology of inv(16)(p13;q22) leukaemia... - Forkhead box P1 overexpression and its clinicopathologic significance in peripheral T-cell lymphoma, not otherwise specifiedSeiji Yamada
Department of Pathology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467 8601, Japan
Hum Pathol 43:1322-7. 2012..The clinicopathologic significance of forkhead box P1 overexpression in peripheral T-cell lymphoma, not otherwise specified, may be different from that in B-cell lymphomas... - Growth inhibition of multiple myeloma cells by a novel IkappaB kinase inhibitorTakaomi Sanda
Department of Molecular and Cellular Biology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-08601, Japan
Clin Cancer Res 11:1974-82. 2005.... - Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietinJianmin Ding
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Science, 1 Kawasumi, Mizuho cho, Mizuho ku, Nagoya 467 8601, Japan
Blood 103:4198-200. 2004..These results show that the Asn505 is an activating mutation with respect to the intracellular signaling and survival of the cells. This is the first report of FET deriving from a dominant-positive activating mutation of the c-MPL gene... - Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell linesTomohiro Kajiguchi
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, 466 8550, Japan
Cancer Sci 97:540-5. 2006..Cotreatment with ATO and the agent, which can induce sustained activation of JNK, might improve the outcome in MM therapy... - Lineage conversion from acute lymphoblastic leukemia to acute myeloid leukemia on rearrangement of the IgH gene in a patient with Down syndromeKazuya Tsuboi
Second Department of Internal Medicine, Nagoya City University Medical School, Japan
Int J Hematol 76:69-73. 2002..It is thought that the leukemic precursor cells of this patient had the potential to differentiate into both lymphoid and myeloid lineages. This case is important for investigating target cells for leukemogenesis in DS... - Alternative translocation breakpoint cluster region 5' to BCL-6 in B-cell non-Hodgkin's lymphomaMarion P Butler
Institute for Cancer Genetics, and the Department of Pathology, Columbia University, New York, NY 10032, USA
Cancer Res 62:4089-94. 2002..The identification of BCL-6 ABR provides new tools for the diagnosis of lymphomas carrying aberrations at 3q27 and deregulated BCL-6 genes... - MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)Masato Ito
Second Department of Internal Medicine, Nagoya City University Medical School, Mizuho-ku, Nagoya 467-8601
Jpn J Cancer Res 93:685-94. 2002..The biological role and mechanism of action of MUM1 in B-CLL / SLL need to be clarified for the development of therapies for patients with the poor prognostic subtype... - The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphomaT Ishida
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Mizuho chou, Mizuho ku, Nagoya shi, Aichi, Japan
Leukemia 20:2162-8. 2006..Collectively, this study strongly indicates that anti-CCR4 mAb could be a novel treatment modality for patients with CCR4-positive HL... - [Proteasome inhibitors for multiple myeloma]Hiroki Yano
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences
Nippon Rinsho 65:601-4. 2007 - Detection of API2-MALT1 fusion transcripts in cytologic specimens of patients with pulmonary mucosa-associated lymphoid tissue lymphomaHiroshi Inagaki
Department of Pathology, Graduate School of Medical Sciences, Nagoya City University, Nagoya
Int J Hematol 82:59-62. 2005..The detection of API2-MALT1 fusion as carried out with these specimens would be useful as an ancillary assay for the diagnosis, staging, and follow-up of pulmonary MALT lymphoma... - Design, synthesis, enzyme inhibition, and tumor cell growth inhibition of 2-anilinobenzamide derivatives as SIRT1 inhibitorsTakayoshi Suzuki
Nagoya City University, Tanabe dori, Mizuho ku, Aichi, Japan
Bioorg Med Chem 17:5900-5. 2009..Among these, compounds 3 and 5 inhibited SIRT1 activity in enzyme assays and suppressed the growth of Daudi and HCT116 cells... - A xeno-transplantable plasma cell leukemia line with a split translocation of the IgH geneKaneyuki Ohbayashi
Department of Infectious Diseases, Nagoya University School of Medicine, 466-8560, Nagoya, Japan
Cancer Genet Cytogenet 144:31-5. 2003..Injection of SACHI cells into NOD/SCID mice generated leukemic plasmacytosis with invasion to liver, spleen, and bone marrow. This cell line may be useful for therapeutic testing as well as analyzing the molecular pathogenesis of PCL... - ABO blood group alleles and the risk of pancreatic cancer in a Japanese populationMakoto Nakao
Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
Cancer Sci 102:1076-80. 2011..Further studies are necessary to define the mechanisms by which the ABO gene or closely linked genetic variants influence PC risk... - Lack of Ku80 alteration in multiple myelomaMiyuki Kato
Second Department of Internal Medicine, Nagoya City University Medical School, Mizuho ku, Nagoya 467 8601, Japan
Jpn J Cancer Res 93:359-62. 2002..Accordingly, Ku80 alteration is unlikely to be involved in MM, in disagreement with a previous study reporting frequent presence of a 69-kD Ku80 variant (Ku86v) with reduced DNA binding activity in MM cells... - Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocationM Seto
Laboratory of Chemotherapy, Aichi Cancer Center, Nagoya, Japan
Oncogene 7:1401-6. 1992.... - Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocationsI Hanamura
Second Department of Internal Medicine, Nagoya City University Medical School, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya 467-8601, Japan
Jpn J Cancer Res 92:638-44. 2001..This finding, together with that of a previous study describing its transforming activity, suggests that the MAFB gene may be one of the targets deregulated by regulatory elements of the IgH gene as a result of t(14;20)... - The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 geneS Iida
Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
Blood 88:4110-7. 1996..These findings suggest that the PAX-5 gene is the target of the t(9;14) in LPL whereby its expression may be deregulated by juxtaposition to IgH regulatory elements, thus contributing to lymphomagenesis... - Inactivation of the E3/LAPTm5 gene by chromosomal rearrangement and DNA methylation in human multiple myelomaY Hayami
Department of Internal Medicine II and Molecular Science, Nagoya City University Graduate School of Medical Science, Nagoya, Japan
Leukemia 17:1650-7. 2003.... - Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancyM Uranishi
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Leukemia 19:1471-8. 2005..Leukemia (2005) 19, 1471-1478. doi:10.1038/sj.leu.2403833; published online 16 June 2005... - MLLT3 gene on 9p22 involved in t(9;11) leukemia encodes a serine/proline rich protein homologous to MLLT1 on 19p13S Iida
Laboratory of Chemotherapy, Aichi Cancer Center Research Institute, Nagoya, Japan
Oncogene 8:3085-92. 1993..As previously found in t(11;19) leukemia, heterogeneous MLL-MLLT3 chimeric mRNAs could be detected by the reverse transcriptase-polymerase chain reaction (RT-PCR) in t(9;11) leukemia samples... - Superior mesenteric venous thrombosis associated with a familial missense mutation (Pro626Leu) in the SHBG-like domain of the protein S moleculeMiyuki Kato
Second Department of Internal Medicine, Nagoya City University Medical School, Japan
Int J Hematol 75:100-3. 2002..Our findings thus suggest that Pro626 in SHBG-like domain 7 may be crucial for in vivo antithrombotic activity of the PS molecule... - Two distinct portions of LTG19/ENL at 19p13 are involved in t(11;19) leukemiaK Yamamoto
Laboratories of Chemotherapy, Aichi Cancer Center Research Institute, Nagoya, Japan
Oncogene 8:2617-25. 1993..Although a chimeric mRNA of KOPN-1 type was rare, its presence suggested that the shared C-terminal portion of 189 amino acids of LTG19 contains important signal(s) for malignant transformation... - Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myelomaS Iida
Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
Nat Genet 17:226-30. 1997..These findings identify a novel genetic alteration associated with MM, with implications for the pathogenesis and diagnostics of this tumour... - IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancyG Hatzivassiliou
Institute of Cancer Genetics, Columbia University, New York, NY 10032, USA
Immunity 14:277-89. 2001..In tumor cell lines with 1q21 abnormalities, IRTA2 expression is deregulated. Thus, IRTA1 and IRTA2 are novel immunoreceptors implicated in B cell development and lymphomagenesis... - Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stressM Ri
Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
Leukemia 24:1506-12. 2010..Thus, a fraction of MM cells may acquire bortezomib resistance by suppressing apoptotic signals through the inhibition of unfolded protein accumulation and subsequent excessive ER stress by a mutation of the PSMB5 gene... - The RCK gene associated with t(11;14) translocation is distinct from the MLL/ALL-1 gene with t(4;11) and t(11;19) translocationsY Akao
Laboratory of Chemotherapy, Aichi Cancer Center Research Institute, Nagoya, Japan
Cancer Res 52:6083-7. 1992..These results, altogether, suggested that two different genes, RCK and MLL/ALL-1, are associated with 11q23 translocation of hematopoietic tumors... - Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesisT Sanda
Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan
Leukemia 19:901-9. 2005..These findings clearly demonstrate that Am80 is a potential inhibitor of angiogenesis caused by the interaction between vascular endothelial cells and myeloma cells, and might be a useful therapeutic agent against MM... - ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myelomaAtsushi Suzuki
Cancer Physiology Project, National Cancer Center Research Institute East, 6 5 1 Kashiwanoha, Kashiwa, Chiba 277 8577, Japan
Oncogene 24:6936-44. 2005..Based on results, we conclude that ARK5 is a transcriptional target of the Large-MAF family through MARE sequence and that ARK5 may in part mediate the aggressive phenotype associated with c-MAF- and MAFB-expressing myelomas... - [Multiple myeloma: from molecular pathogenensis to the development of molecular targeting therapies]Shinsuke Iida
Rinsho Ketsueki 45:1160-7. 2004 - Global real-time quantification/reverse transcription-polymerase chain reaction for detecting proto-oncogenes associated with 14q32 chromosomal translocation in multiple myelomaEmi Tajima
Haematologica 90:559-62. 2005..This technique is an alternative method of detecting 14q32 rearrangements and allows investigation of the relationship between proto-oncogene expression and clinical features... 
Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSFHiroki Yano
Br J Haematol 140:586-9. 2008- Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study GroupChihiro Shimazaki
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 620 9566, Japan
Int J Hematol 81:342-8. 2005..5% and 18.8%, respectively. These observations suggest that RIST is feasible with reliable donor engraftment and relatively low transplantation-related mortality in Japanese MM patients... - [Molecular pathogenesis of multiple myeloma]Shinsuke Iida
Rinsho Ketsueki 47:196-203. 2006 - Molecular-cytogenetic characterization of non-Hodgkin's lymphoma with double and cryptic translocations of the immunoglobulin heavy chain geneYumiko Kanda-Akano
Division of Hematology and Oncology, Department of Internal Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
Leuk Lymphoma 45:1559-67. 2004..Furthermore, FISH identified one novel (9q22) and one cryptic chromosomal breakpoints (6q27) involved in IGH translocation... - [Recent progress in the treatment of multiple myeloma]Shinsuke Iida
Rinsho Ketsueki 48:91-9. 2007 - [The molecular mechanisms of myelomagenesis]Ichiro Hanamura
Department of Internal Medicine, Aichi Medical University, School of Medicine
Nippon Rinsho 65:203-14. 2007 - [Treatment for multiple myeloma: current status and future strategy in Japan]Shinsuke Iida
Rinsho Ketsueki 49:1368-73. 2008